Geode Capital Management LLC Sells 306,763 Shares of Boston Scientific Corporation $BSX

Geode Capital Management LLC reduced its position in Boston Scientific Corporation (NYSE:BSX) by 0.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 32,383,765 shares of the medical equipment provider’s stock after selling 306,763 shares during the quarter. Geode Capital Management LLC’s holdings in Boston Scientific were worth $3,073,440,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in BSX. FWL Investment Management LLC purchased a new stake in shares of Boston Scientific in the second quarter worth approximately $26,000. Murphy & Mullick Capital Management Corp lifted its stake in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares during the last quarter. United Community Bank lifted its stake in shares of Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares during the last quarter. Colonial Trust Co SC lifted its stake in shares of Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 231 shares during the last quarter. Finally, Bangor Savings Bank lifted its stake in shares of Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 142 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Negative Sentiment: Boston Scientific cut its 2026 growth outlook and signaled softer demand in WATCHMAN and urology, raising concerns that near-term revenue growth may underdeliver versus prior expectations. Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth Guidance
• Negative Sentiment: Management also highlighted competitive pressure in electrophysiology and a more cautious near-term operating backdrop, which added to investor concerns and helped trigger the stock’s sharp decline. Boston Scientific (BSX) slides after management cuts 2026 growth outlook
• Neutral Sentiment: On the positive side, Boston Scientific still has an active product pipeline, and one recent device trial reported strong efficacy, which could support the longer-term growth story if commercial adoption follows. Boston Scientific (BSX) Device Succeeds in Over 93% of Patients in Its Pivotal Trial
• Neutral Sentiment: The company also deployed capital into a large private-company stake, which may appeal to long-term strategic investors but is not the main driver of the stock’s move today. Boston Scientific Is Betting $1.5 Billion on a Massive Market — and Wall Street Is Paying Attention

Insiders Place Their Bets

In other Boston Scientific news, Director Cheryl Pegus purchased 1,770 shares of the stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average price of $56.49 per share, with a total value of $99,987.30. Following the transaction, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David C. Habiger purchased 2,250 shares of the stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $55.92 per share, with a total value of $125,820.00. Following the transaction, the director directly owned 13,878 shares in the company, valued at approximately $776,057.76. This trade represents a 19.35% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased 9,800 shares of company stock worth $554,012 in the last three months. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on BSX. Bank of America decreased their price target on Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Royal Bank Of Canada decreased their price target on Boston Scientific from $105.00 to $100.00 and set an “outperform” rating for the company in a research note on Thursday, April 23rd. Canaccord Genuity Group decreased their price target on Boston Scientific from $109.00 to $71.00 and set a “buy” rating for the company in a research note on Thursday, April 23rd. Evercore lowered their price objective on shares of Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Finally, Oppenheimer set a $90.00 target price on shares of Boston Scientific in a research note on Thursday, April 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $92.29.

Boston Scientific Price Performance

Shares of BSX stock opened at $50.34 on Thursday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The company has a market capitalization of $74.82 billion, a P/E ratio of 21.06, a P/E/G ratio of 1.06 and a beta of 0.62. The company’s 50-day simple moving average is $61.13 and its two-hundred day simple moving average is $79.19. Boston Scientific Corporation has a one year low of $50.04 and a one year high of $109.50.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities analysts anticipate that Boston Scientific Corporation will post 3.38 EPS for the current year.

Boston Scientific announced that its Board of Directors has authorized a stock repurchase program on Monday, May 18th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.